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ABSTRACT 
Bacterial aromatic polyketides include many therapeutic agents and are biosynthesized by type II 
polyketide synthases (PKSs). In the actinorhodin type II PKS, the first polyketide modification is 
a regiospecific C9-carbonyl reduction, catalyzed by the ketoreductase (actKR). Our previous 
studies identified the actKR 94-PGG-96 motif as a determinant of stereospecificity (Javidpour, et 
al., 2011). The molecular basis for reduction regiospecificity is, however, not well understood. In 
this study, we examined the activities of 20 actKR mutants through a combination of kinetic 
studies, PKS reconstitution, and structural analyses. Residues have been identified which are 
necessary for substrate interaction, and these observations have suggested a structural model for 
this reaction. Polyketides dock at the KR surface and are steered into the enzyme pocket where 
C7-C12 cyclization is mediated by the KR before C9-ketoreduction can occur. These molecular 
features can potentially serve as engineering targets for the biosynthesis of novel, reduced 
polyketides. 
 
HIGHLIGHTS 
• ActKR surface arginines are important for ACP-binding and activity toward polyketides 
• In contrast to the S-specific P94L actKR, mutant V151L displays R-stereospecificity 
• ActKR is proposed to mediate C7-C12 polyketide cyclization prior to C9-ketoreduction 
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INTRODUCTION 
 Polyketide natural products are a large, diverse class of secondary metabolites with 
important biological activities (Crawford and Townsend, 2010; Zhan, 2009). Many 
pharmaceutical compounds are polyketide-based, including antibiotics (tetracycline), anti-cancer 
agents (daunorubicin), and immunosuppressants (FK506) (Cane, et al., 1998). Polyketide 
biosynthesis is driven by the polyketide synthase (PKS), which is genetically and functionally 
similar to fatty acid synthase (Hopwood, 1997). PKSs are generally divided into three classes 
(Shen, 2003), though the focus of this study are type II PKSs found in bacteria, which 
biosynthesize aromatic polyketides, such as actinorhodin (Malpartida and Hopwood, 1984). In 
the actinorhodin (act) type II PKS (Figure 1), a linear poly-β-keto chain is biosynthesized by the 
minimal PKS, consisting of the dimeric ketosynthase-chain length factor (KS-CLF) and an acyl 
carrier protein (ACP) (Malpartida and Hopwood, 1984). Biosynthesis is initiated by an acetate 
starter unit derived from CLF-mediated decarboxylation of a malonyl-ACP thioester. Subsequent  
chain elongation occurs through decarboxylative condensation of malonyl-based units to this 
starter, producing the final octaketide (16-carbon) intermediate (Das and Khosla, 2009). The first 
modification of the nascent polyketide chain is catalyzed by the actKR, which regiospecifically 
reduces a single carbonyl group (typically at C9) to a hydroxyl group. This modification is 
thought to occur after cyclization between C7 and C12 occurs, which forms the first ring, a 
process that may also be directed by the ketoreductase (McDaniel, et al., 1993). Heterologous 
expression and in vitro reconstitution experiments have demonstrated that, in the absence of 
modifying enzymes, the act minimal PKS produces both the correctly C7-C12 cyclized SEK4 as 
well as the aberrantly C10-C15 cyclized SEK4b. When actKR is present, however, the dominant 
product becomes mutactin (C7-C12 cyclized), further suggesting that correct cyclization is 
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dependent on reductase activity (Khosla, et al., 1993; McDaniel, et al., 1994; Zawada and 
Khosla, 1999). 
 Type II ketoreductases can potentially be utilized in organic synthesis applications and in 
engineered biosynthesis (Broussy, et al., 2009; Grau, et al., 2007; Jacobsen, et al., 1998; Truppo, 
et al., 2007). This would require an in-depth understanding of KR-substrate interactions, 
including the factors that dictate regio- and stereospecificity. Our previous structural and 
biochemical analyses led to the identification of the actKR 94-PGG-96 motif as a determinant of 
stereospecificity as well as residues that interact with the inhibitor emodin (Javidpour, et al., 
2011; Korman, et al., 2008). Furthermore, docking studies suggested a region on the actKR 
surface that could act as the site of interaction between KR and ACP (Javidpour, et al., 2011). In 
order to fully realize the potential of KR for engineered reduction, a detailed assessment of the 
molecular basis for C9-regiospecificity and the possible role of actKR in first-ring cyclization is 
required. 
 The aim of this work is to identify actKR residues that mediate interactions with the 
natural polyketide substrate, the NADPH cofactor and the carrier protein, as well as residues that 
direct C9-regiospecific ketoreduction. We present the molecular features of actKR involved in 
recognizing and directing the polyketide intermediate for C9-ketoreduction. This is supported by 
kinetic and in vitro PKS reconstitution assay data for 20 actKR mutants. High-resolution 
crystallographic structures for three of the mutants are also presented. We targeted specific 
actKR residues for mutagenesis based on previous structural and biochemical analyses of wild-
type (WT) and P94L actKR, both in the presence or absence of the inhibitor emodin (Javidpour, 
et al., 2011; Korman, et al., 2004; Korman, et al., 2008). These mutations can be subdivided into 
three groups associated with surface, substrate binding pocket, and the α6-α7 loop. Significantly, 
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we have shown that a single mutation in the actKR substrate pocket can switch the 
stereospecificity between S-dominant and R-dominant, which contradicts the results of type I 
polyketide KR mutations (Baerga-Ortiz, et al., 2006; Castonguay, et al., 2008; Holzbaur, et al., 
1999; Holzbaur, et al., 2001; Keatinge-Clay, 2007; Keatinge-Clay and Stroud, 2006; O'Hare, et 
al., 2006; Ostergaard, et al., 2002; Siskos, et al., 2005). These results form the basis for a new 
model of KR-mediated C7-C12 first-ring cyclization that occurs within the enzyme binding 
pocket prior to ketoreduction. 
 
RESULTS 
 
Overall Strategy 
 Based on previous structural and biochemical analyses of wild-type and P94L actKR 
(Javidpour, et al., 2011; Korman, et al., 2004; Korman, et al., 2008), we proposed three groups of 
mutations: surface mutations to evaluate protein-protein interactions and long-range effects on 
enzyme activity, substrate binding pocket mutations to assess stereospecificity and catalytic 
efficiency, and finally mutations in the α6-α7 loop to determine if this flexible region plays a 
significant role in catalysis. Trans-1-decalone and tetralol were used as substrate analogs to 
kinetically assay catalytic efficiency and substrate specificity of the reduction (Tables 1, 2, and 
S1). Trans-1-decalone, which has previously been used as a model substrate to assay 
ketoreductase activity in both fatty acid synthase and PKS (Dutler, et al., 1971; Ostergaard, et al., 
2002), was shown to be a more effective substrate for the actKR than 1-tetralone (Korman, et al., 
2008).  
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 Extensive studies of type I polyketide KRs have shown that their mutation often results in 
a mixture of enantiomeric reduced products and that multiple residues, located both within and 
distal to the active site, determine the stereospecificities of type I KRs (Baerga-Ortiz, et al., 
2006; Castonguay, et al., 2008; Holzbaur, et al., 1999; Holzbaur, et al., 2001; Keatinge-Clay, 
2007; Keatinge-Clay and Stroud, 2006; O'Hare, et al., 2006; Ostergaard, et al., 2002; Siskos, et 
al., 2005). In contrast, our previous studies of the type II polyketide KRs have shown that 
whereas wild-type actKR displays a 3:1 preference for S- over R-stereochemistry based on 
catalytic specificities for oxidation of tetralol enantiomers, the P94L mutation is sufficient to 
switch the in vitro stereospecificity of actKR to S-dominant, with no detectable activity toward 
R-tetralol. (Javidpour, et al., 2011). The term S-dominant herein is used to describe actKR 
mutants that display higher preference for S- over R-tetralol as compared to the wild-type 
enzyme. Our previous results also implied that long-ranged effects might be important for 
stereospecificity. We therefore constructed binding pocket mutants to determine how these 
residues affect KR stereospecificity. ActKR mutants were also assayed through in vitro 
reconstitution of the extended minimal PKS (act min PKS plus actKR). With the exception of 
evaluation of surface arginine mutants where actACP was used for accurate ACP-KR binding 
measurement, actACP was substituted with the orthologous frenN ACP for all reconstitution 
assays. The frenN ACP can be expressed at higher levels than the actinorhodin carrier protein 
and forms a stable protein complex (Khosla, et al., 1993). Products from mutant KR 
reconstitution experiments were compared to those from both the act min PKS or the extended 
minimal complex. Activity, relative to that of wild-type actKR, was assessed by comparing the 
ratio of the area of the mutactin peak to the average of both SEK4 and SEK4b peaks.  
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Surface Residue Mutants Display Greatly Diminished Activity and KR-ACP Interactions 
 Surface residues were mutated to assess whether R38A, R65A, R93A and D109E/R of 
actKR form a patch that interacts with ACP (Figure 2A). Previous in silico docking and 
mutational analyses suggested that the arginine residues, along with D109, form a charged 
groove that promotes complementary interactions with both helix II and the phosphopantetheine 
(PPant) group of the ACP (Korman, et al., 2008; Tang, et al., 2006). The D109 β-carboxyl group 
is within hydrogen-bonding distance of both the R65 and R93 side-chains. This interaction may 
maintain the structure of the phosphate-binding groove.  
 PKS reconstitution analysis showed that mutants R65A and R93A produced less mutactin 
than wild-type actKR, based on the respective mutactin:SEK4(b) ratios, while reconstitution 
with R38A actKR led to no detectable level of mutactin (Figure 3). To determine the dissociation 
constants (Kd) between actACP and actKR, separate fluorescence binding assays were measured 
(Figure S3). Here, the R38A actKR mutant displayed the weakest interaction (Kd 1.52 µM vs. 
0.20 µM for wild-type). Mutants R65A and R93A both displayed a Kd value of 0.53 µM. The 
D109E actKR mutation had little effect on mutactin production (Figure 3), catalytic turnover in 
the trans-1-decalone assay, or activity when assayed with S- and R-tetralol (Table 1). The D109R 
mutant, in comparison, shows a 30-fold reduction in trans-1-decalone turnover and is inactive 
when assayed with S- and R-tetralol (Tables 2 and S1). The conservative D109E mutation is 
therefore, tolerated, while D109R strongly influences catalysis and may destabilize the adjacent 
arginine patch. NADPH binding to both wild-type actKR and the three arginine mutants (R38A, 
R65A, and R93A) was also determined using a fluorescence binding assay. A Kd of 1.52 µM for 
wild-type actKR was obtained, a value similar to that previously determined (5 µM, Korman et 
al., 2008). The R38A and R93A actKR mutants showed approximately 3-fold and 8-fold 
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reductions in NADPH binding respectively, while R65A was unchanged. These results suggest 
that residues R38, R65, R93, and D109 are important for KR-ACP binding and activity. 
Mutations targeting the surface residues lead to disruption of the KR-ACP interaction and 
decreased activity toward the PPant-tethered polyketide substrates. 
 
KR Pocket Mutants: Non-Polar Side-Chains are Necessary for Substrate Interactions 
 The amphipathic nature of the polyketide intermediate requires both hydrophilic and 
hydrophobic residues for substrate-binding and the prevention of premature polyketide 
cyclization (Keatinge-Clay, et al., 2004). With this in mind, a number of substrate binding 
residues were identified, based on actKR-emodin co-crystal structures (Korman, et al., 2008). 
These mutated residues include S144C, T145A, G146V, V151A/L, A154G, F189A/W, M194W, 
and V198A/G (Figure 2B and 2C).  
 Mutants S144C and G146V were specifically designed to assess their role in C9-
oxyanion stabilization during polyketide reduction. The S144C mutant was constructed to test 
substitution of the serine β-hydroxyl with a weaker hydrogen-bonding functional group. Residue 
G146 is located behind catalytic residues S144 and Y157. Mutation of this glycine to the larger, 
non-polar valine residue is expected to sterically hinder polyketide binding in the active site by 
disrupting the arrangement of S144 and Y157. As expected, mutants S144C and G146V did not 
produce any detectable levels of mutactin (Figure 3). Both mutations exhibited low activity 
toward S- and R-tetralol, and were inactive when assayed with trans-1-decalone (Tables 1, 2, and 
S2).  
V151 is crucial for substrate recognition. The V151A mutant was inactive toward both 
trans-1-decalone and tetralol (Tables 1, 2, and S1). V151 is located ~5 Å from Y157 near the 
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base of the monomer cleft (Figure 2B). The branched side-chain of residue 151 extends into the 
binding pocket where non-polar interactions orient the substrate prior to reduction. In contrast, 
the conservative V151L mutation displayed kcat and Km values for trans-1-decalone and R-
tetralol turnover that were comparable to those of wild-type actKR, supporting the hypothesis 
that a large hydrophobic side-chain is required at this position to steer substrate-binding and 
sustain reductase activity. V151L did, however, produce 20-fold less mutactin than wild-type 
actKR (Figure 3). Here the leucine side-chain may interfere with polyketide-binding, further 
highlighting the requirement for precise steric control within the active site. This may explain the 
high sequence conservation of V151 amongst type II PKS KRs. 
 The value for kcat/Km of A154G actKR in the trans-1-decalone  assay was similar to that 
of the wild-type enzyme, while the activity using both S- and R-tetralol substrates was also 
relatively high compared to the other mutants (Tables 2 and S1). F189 mutations (F189A and 
F189W), however, displayed the lowest activity toward trans-1-decalone (Table 1). Activity of 
both mutants was also significantly reduced where R-tetralol was used as the substrate, though 
turnover of the S-enantiomer by the F189W mutant enzyme approached wild-type levels. The 
F189W mutant also produced much lower levels of mutactin when compared to wild-type 
actKR, while mutactin production in F189A was almost undetectable (Figure 3). Assay results 
for the F189 mutants suggest that, similar to V151, residue F189 is crucial for enzyme-substrate 
interaction. 
 Mutation M194W abolished mutactin production, and reduced trans-1-decalone turnover 
to 5% of wild-type. The actKR containing this methionine-tryptophan mutation was completely 
selective for the S-enantiomer of tetralol. Here the bulky tryptophan may sterically clash with the 
NADPH nicotinamide, residue P94, or with polyketide binding. 
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 The V198G mutation drastically reduces mutactin production and shows markedly 
decreased activity towards both S- and R-tetralol (Table 2). A V198A mutation in comparison 
only shows moderate changes in these assays, with a small increase in R-tetralol selectivity. 
Progressive reduction of the hydrophobic side chain at this position clearly exerts strong effects 
on enzyme activity and fidelity of polyketide chain processing.   
 
Aromatic Interaction in the α6-α7 Loop Region May Be Important for Substrate 
Recognition 
 The type II PKS KRs possess a distinctive 11-residue insertion in the α6-α7 loop (actKR 
residues 199-209) (Figure S2) (Korman, et al., 2008). This loop is the least conserved region in 
the short-chain dehydrogenase/reductase (SDR) superfamily of proteins, to which actKR 
belongs, and may contribute to SDR substrate specificity (Oppermann, et al., 2003). Residue 
Y202 is highly conserved among the type II KRs (Fig S2A). Our previous studies suggested that 
α6-α7 loop residues may play an important role in recognizing polyketide intermediates 
(Javidpour, et al., 2011). We therefore constructed mutants Y202A and Y202F in order to 
evaluate the respective contributions of an aromatic side-chain and a phenolic hydroxyl group 
toward substrate recognition and activity. 
 The Y202 mutants displayed activities toward trans-1-decalone and tetralol that are 
comparable to those of wild-type (Tables 1, 2, and S1). However, mutactin production by the 
Y202A mutant is reduced, suggesting that complete removal of the aromatic side chain 
negatively influences substrate turnover. Y202 may be involved in π-π interactions with W206 
that stabilize the α6-α7 loop conformation and might therefore play a structural rather than a 
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catalytic role. This may also explain why aromatic pairs are highly conserved amongst type II 
PKS KRs (Fig. S2A) at these positions. 
 Two further residues, R177 that packs against the α6-α7 loop from an adjacent KR 
subunit in the tetramer, and R220 that packs against Y202, were both mutated to alanine (Tables 
1-2, S1, Fig. 3). Neither mutation had a significant effect in any of the activity assays, or 
NADPH or ACP binding.  
 
Structural Analysis of V151L, F189W, and Y202F ActKR 
 Three of the mutants that displayed intriguing assay results were crystallized and their 
structures solved; V151L (for its R-tetralol specificity), F189W (for its S-tetralol specificity), and 
Y202F (to probe the long-range effect of the α6-α7 loop). Overall, the structures are very similar 
to the NADPH-bound structures of wild-type and P94L actKR (Javidpour, et al., 2011). The 
alignment root-mean-square deviations (RMSD) of the mutant structures relative to wild-type 
are: 0.41, 0.44, and 0.35 Å for V151L, F189W, and Y202F, respectively, and 0.41, 0.55, and 
0.40 relative to P94L. The alignments of the catalytic residues (N114, S144, Y157, and K161) 
and the NADPH cofactor have similar positions and conformations (Figure 4A). The three 
mutant structures show that while mutations significantly altered observed activities and regio- 
and stereospecificities in three different assays, the overall protein conformations are not 
changed.  
 Despite the high overall similarity, there are structural differences that distinguish the 
three mutants from the previously characterized crystal structures (Korman, et al., 2004) 
(Korman, et al., 2008). Alignment of the B subunits shows that in the V151L, F189W, and 
Y202F mutants, the α6-α7 loop adopts a more closed conformation than the wild-type (Figure 4 
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and S2B). In these mutants M194 becomes extended and is potentially involved in non-polar 
interactions with P94. When V151L is aligned to wild-type actKR, L151 of subunit A extends 
into the substrate pocket in a similar conformation to V151. In the mutated subunit B, however, 
L151 points toward the α6-α7 loop, thus creating a closed conformation and a smaller substrate 
pocket (Figure 4B). Similarly, in F189W the tryptophan aromatic ring overlaps with the wild-
type residue F189, while L258 interacts with W189, again resulting in a smaller substrate pocket 
in monomer A. In the wild-type enzyme, the Y202 side-chain potentially forms a water-mediated 
hydrogen bond with the H153 backbone carbonyl and consequently points away from the α6-α7 
loop. In the F202 mutant, however, the phenylalanine ring rotates back into the substrate binding 
pocket, possibly due to loss of this hydrogen bonding interaction (Figure 4D). The V151L, 
F189W, and Y202F mutations therefore result in a smaller substrate pocket for monomer B, 
which contributes to the observed low mutant enzyme activities. The altered pocket shape also 
imposes more steric hindrance in V151L, resulting in the observed substrate inhibition (Tables 2 
and S1). 
 
Docking Analyses: The Molecular Basis for V151L and F189W Tetralol Assay Results 
 Mutant V151L displayed unusual activity toward tetralol, with almost threefold higher 
activity toward the R-stereoisomer than that of wild-type (Tables 2 and S1). When assayed with 
S-tetralol, however, we observed substrate inhibition at high (> 2 mM) S-tetralol concentrations. 
Both tetralol stereoisomers were docked within the V151L actKR substrate binding pocket using 
the program GOLD (Verdonk, et al., 2003). The docking results yielded similar positions and 
conformations for each stereoisomer, whereas for the wild-type actKR structure, R-tetralol does 
not consistently dock. In the V151L mutant, the R-tetralol aromatic ring consistently docks 
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within the opening of the substrate binding cleft (Figure S1A), consistent with the high kcat/Km of 
this mutant for R-tetralol relative to the wild-type enzyme. In contrast, the simulations showed 
that S-tetralol docks with the aromatic ring near residues T145, F189, and L258, which avoids 
clashes with L151. S-tetralol may, therefore, be lodged between these three residues, causing the 
enzyme to be “trapped” in a substrate-bound state (ES) by the high affinity for S-tetralol and 
resulting in the observed substrate inhibition phenomenon. To the best of our knowledge, such a 
phenomenon has not been reported for type I polyketide KRs before. This result also 
demonstrates that the type II polyketide KR is unique in its ability to switch stereospecificity 
through a single mutation. 
 To ascertain the molecular basis for the high F189W stereospecificity, S- and R-tetralol 
were again docked within the enzyme binding pocket. Analysis suggests that the 
stereospecificity may arise from a combination of steric hindrance, (as for P94L or M194W 
actKR), as well as from the W189 indole group, which may adopt a different rotamer 
conformation upon substrate-binding.  This allows π-π interactions with the S-tetralol benzyl 
moiety, but not with the R-stereoisomer (Figure S1B). The adoption of a different rotameric state 
is supported by the crystallographic data, wherein there is well-defined 2Fo-Fc electron map 
density for W189 in subunit A of the mutant, but weaker density for the residue in subunit B. 
This suggests the presence of multiple rotamers in subunit B. The steric effect exerted by W189 
thus steers the mutant toward S-dominant stereospecificity. 
 
DISCUSSION 
 Based on the results of kinetic and reconstitution assays, structural analyses, docking 
simulations, and incorporation of previous studies (Javidpour, et al., 2011; Korman, et al., 2004; 
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Korman, et al., 2008), we propose the following model for polyketide docking, entrance into the 
substrate pocket, C7-C12 first-ring cyclization, and stereospecific ketoreduction by a type II 
polyketide KR that accounts for the observed properties of wild-type and mutant actKR (Figure 
5). 
PPant-Tethered Polyketide Docking 
 Docking results described in this paper, combined with studies of the homologous S. 
coelicolor SCO1815 KR (Javidpour, et al., 2011; Tang, et al., 2006), identify an arginine patch 
as the putative docking site of the PPant phosphate (Figure 2A). In the tetrameric actKR 
structure, the arginine patch is accessible on each monomer and is not hindered by any 
neighboring molecule. The assay results for the R38A, R65A, and R93A mutants, which 
displayed decreased reconstitution activity and interaction with ACP, lend further support to the 
importance of the arginine patch for enzyme activity. 
 
Access to the ActKR Substrate Pocket 
 The docked PPant carrying the polyketide intermediate must now access the actKR active 
site. Two openings are seen in the surface representation of wild-type actKR subunit A, 
separated by P94 and the M194, which hereafter are referred to as “gate” residues (Figure 5A). 
The importance of M194 is supported by assays of the M194W mutant, which produced less 
mutactin than expected based on the trans-1-decalone assay. The mutant tryptophan may 
sterically hinder polyketide docking, or block access to the active site. Entrance to the enzyme 
pocket from the opening immediately proximal to the arginine patch is further blocked by the 
NADPH pyrophosphate moiety. The polyketide must, therefore, enter the pocket through the 
cleft below the P94 and M194 gate residues. 
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Steering of Polyketide toward the Active Site and Monomer-Closing 
 The polyketide substrate must be directed by the “steering” residues, which include the 
hydrophobic V198, F189, and V151. These residues must be non-polar and not glycine as 
suggested by the assay results for V198G, which produced less mutactin than expected. The 
V198 side-chain protrudes into the enzyme cleft, effectively steering the PPant arm and 
polyketide intermediate toward the active site residues (Figure 5B). V198 may also participate in 
non-polar interactions with the end of the PPant arm distal from ACP. Furthermore, the V151 
and F189 side-chains define the narrow cleft and limit substrate movement. This is supported by 
assays of the V151 mutants: V151A is inactive toward trans-1-decalone, whereas V151L is 
active and leads to mutactin production, suggesting the need for a bulky residue at this position. 
Similarly, the need for a bulky residue at position 189 is supported by assays of F189A and 
F189W. The latter mutant produced more mutactin when compared to F189A, despite the 
presence of the bulky tryptophan. 
 
KR-Mediated C7-C12 First-Ring Cyclization and C9-Ketoreduction 
 Having been steered towards the active site, the linear polyketide is then positioned such 
that the C11-carbonyl can interact through hydrogen-bonding with T145, which is highly 
conserved among type II KRs. This interaction could sufficiently lower the pKa of the C12 α-
protons (Gerlt, et al., 1991) such that a proton can be abstracted by water in the substrate binding 
pocket. This leads to C7-C12 cyclization, with the C7-oxyanion stabilized by water-mediated 
hydrogen-bonding to the highly conserved S158. This mechanism is supported by assays of 
T145A, which displayed activity toward trans-1-decalone (Table 1), but intriguingly did not 
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produce any detectable level of mutactin. Other mutants less active toward trans-1-decalone than 
T145A were able to produce some mutactin (Figure 3). We therefore propose that T145 is 
involved in C7-C12 polyketide cyclization through hydrogen-bonding with the C11-carbonyl, 
which lowers the pKa of the C12-protons via enolate stabilization. 
 The model presented in this paper helps to explain how the actKR affects cyclization 
specificity such that all downstream products of the PKS are cyclized between C7 and C12. In 
the absence of KR, approximately equal amounts of SEK4 (C7-C12 cyclized) and SEK4b (C10-
C15 cyclized) are produced by the minimal PKS (Figure 1). The KR may, therefore, serve as a 
scaffold that steers the polyketide substrate toward T145 for C7-C12 cyclization, which then 
forces the C9-carbonyl within the active site for regiospecific ketoreduction (Figure 5C). If the 
polyketide intermediate were not cyclized, the C9-carbonyl would be able to adopt a number of 
orientations. In addition, C7-C12 cyclization would restrict the mode of polyketide binding 
within the active site, which explains why actKR may produce only one enantiomer of mutactin 
in vivo (Javidpour, et al., 2011). The absence of hydrogen bond donation from T145A would 
prevent directed-cyclization from occurring, which in turn would compromise ketoreduction. As 
a result, the ACP-bound polyketide may pull out of the KR pocket and spontaneously cyclize in 
solution to yield SEK4 and SEK4b. 
 We propose that during ketoreduction, actKR achieves a closed-state when the α6-α7 
loop moves toward the opposite side of the enzyme cleft, with π-π interactions between the 
highly conserved residues 202 and 206 maintaining the loop conformation as it closes in on the 
polyketide substrate (Figure S2). This motion effectively traps the polyketide within the enzyme, 
yet leaves openings for water to enter the binding site. The monomer opens once catalysis is 
complete, allowing the ACP-bound reduced polyketide to leave the enzyme. In this regard, the 
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binding site of actKR is distinct from that of actKS-CLF (Keatinge-Clay, et al., 2004), where an 
amphipathic tunnel is needed for polyketide elongation toward the KS-CLF gate residues (Tang, 
et al., 2003). The situation is arguably more complex for the actKR, however, as a tunnel would 
prevent KR from mediating cyclization. The actKR pocket must, therefore, be large enough to 
accommodate a monocyclized polyketide, yet still maintain tight interactions with the substrate 
so that release does not occur before reduction. The bulky residues, V151, F189, and V198, are 
necessary to both steer and cradle the polyketide in position until catalysis is complete. 
 
SIGNIFICANCE 
 Type II polyketides include many antibiotics and chemotherapeutic agents that are of 
interest to the pharmaceutical industry (Saleem, et al., 2010). The type II polyketide KR is an 
important modification enzyme that introduces chemical diversity in polyketides by reducing 
intermediates with high regio- and stereospecificity and possibly mediating a specific C7-C12 
first-ring cyclization. Previous biochemical and structural analyses have identified the “PGG” 
motif as important for in vitro stereospecificity (Javidpour, et al., 2011; Korman, et al., 2008). In 
this work, we depart from the status quo to elucidate the roles of surface, binding pocket, and 
loop-region residues of actKR through a suite of informative tools: site-directed mutagenesis, 
kinetic assays, and PKS reconstitution assays. Highly consistent results from three different 
assays of 20 mutants offer a rich array of information about the type II KR, such as the 
identification of bulky hydrophobic pocket residues that are necessary to serve as “gate” and 
“steering” residues for substrate binding. We have also shown that a single mutation (V151L) 
converts stereospecificity to R-dominant, as opposed to other single mutations that result in S-
dominant stereospecificity. Furthermore, the T145 mutant offered the first experimental support 
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to the suggestion that this type II KR fosters first-ring cyclization between C7 and C12. The 
results support a proposed model for polyketide docking, entrance into the KR enzyme pocket, 
cyclization, and ketoreduction that accounts for the high specificity of actKR. The molecular 
features identified in this work will serve as protein engineering targets for rational control of 
KR specificity to produce new polyketides with pharmaceutical potential. 
 
EXPERIMENTAL PROCEDURES 
 
ActKR, ActKS-CLF, Holo-FrenN ACP and MAT Protein Expression and Purification 
 Recombinant wild-type or mutant actKR, actKS-CLF, holo-ACP and MAT proteins were 
express and purified as described previously (Korman, et al., 2004; Korman, et al., 2008; 
Matharu, et al., 1998); (Li, et al., 2003); (Kumar, et al., 2003). Additional details can be found in 
the Supplemental Information. 
 
In Vitro trans-1-Decalone, Tetralol, and In Vitro PKS Reconstitution Assays for ActKR 
Activity 
 Steady-state kinetic parameters for wild-type and mutant actKR were determined by 
monitoring reduction of trans-1-decalone in the presence of NADPH, by monitoring oxidation of 
S-(+)- or R-(-)-tetralol in the presence of NADP+, and PKS reconstitution assay. Steady-state 
kinetic data are listed in Tables 1, 2 and S1. Additional details can be found in the 
Supplementary Information. 
 
In Vitro Tetralol Assay for ActKR Stereospecificity 
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 Steady-state kinetic parameters for wild-type and mutant actKR were determined by 
monitoring oxidation of S-(+)- or R-(-)-tetralol in the presence of NADP+. Summarized kinetic 
data are listed in Table 2 and detailed steady-state data in Table S1. Additional details can be 
found in the Supplemental Information. 
 
ACP Fluorescence Binding Assay.  To gauge interaction between ACP and either wild-type, or 
mutant KR, actACP was titrated into a solution of actKR containing 25 µM NADPH and 1 mM 
DTT. Fluorescence emission spectra were collected over the range of 320-380 nm at a 295-nm 
excitation wavelength (tryptophan fluorescence). For NADPH binding, increasing concentrations 
of NADPH (0-38µM) were titrated in actACP (1µM) and the NADPH fluorescence was excited 
at 340nm and monitored between 400-500nm. Additional details can be found in the 
Supplemental Information. 
 
Protein Crystallization, Data Collection, and Structure Solution 
Experimental procedures and statistics for structure determination of the V151L, F189W, 
and Y202F actKR mutants can be found in the Supplemental Information. 
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FIGURE LEGENDS 
 
Figure 1. Schematic of the Actinorhodin Type II PKS 
The minimal PKS synthesizes a 16-carbon polyketide intermediate that, in the absence of KR, 
spontaneously forms unreduced products SEK4 1 (C7-C12 first-ring cyclization) and SEK4b 2 
(C10-C15 first-ring cyclization). KR regiospecifically reduces C9 yielding a C7-C12 cyclized 
polyketide that forms mutactin 3 as the major product. That all downstream products, including 
SEK34 5, DMAC 6, and actinorhodin 7, are C7-C12-cyclized suggests that KR also plays a role 
in the determination of cyclization specificity. 
 
Figure 2. ActKR Residues Targeted for Site-Directed Mutagenesis 
(A) Arginines 38, 65, and 93 (green) are proposed to stabilize the PPT phosphate group during 
the binding of polyketide intermediate (yellow ball and sticks). 
(B) Pocket residues (green) near catalytic S144 and Y157 (magenta) that interact with 
cocrystallized emodin (orange). NADPH (green ball and sticks) and P94 (teal) are shown for 
perspective and the location of G146 is highlighted in blue. 
(C) Residues F189, M194, and V198 (green) relative to S144, Y157, and emodin. 
 
Figure 3. HPLC Chromatograms of Products from In Vitro PKS Reconstitution Assays 
The traces are divided into five panels for clarified viewing, with each panel including the traces 
for minimal PKS alone and with wild-type actKR as references. Products include SEK4 1, 
SEK4b 2, and mutactin 3. For each active KR, the number to the right of a trace denotes the 
respective mutactin:SEK4(b) ratio. The general mutation locations are also listed to the right of 
the panels. 
 
Figure 4. Mutant ActKR Structural Analysis 
(A) (Left) Alignment of monomer B of V151L (magenta), F189W (blue), and Y202F (yellow) to 
that of wild-type actKR (green). Although the catalytic residues and NADPH cofactors align 
well, the mutant monomers are in a closed conformation relative to wild-type, as seen by the 
shifts in the labeled α6-α7 loops and extended M194 side-chains (right). 
(B) Residue 151 extends into the substrate pocket similarly in monomer A of wild-type (green) 
and V151L (magenta) (left), but L151 in the mutant monomer B points more toward the α6-α7 
loop, creating a smaller substrate pocket (right) 
(C) The aromatic plane of W189 in the F189W mutant (blue) coincides with that of wild-type 
F189 (green). L258 may hydrophobically interact with W189, limiting the substrate pocket size. 
(D) Residue 202 overlaps when monomer A of wild-type (green) and Y202F (yellow) are 
aligned (left), but in monomer B (right), the wild-type Y202 points away from the substrate 
pocket while the mutant F202 points within the pocket. 
 
Figure 5. Stereo Images of Proposed Interactions between Polyketide and Wild-Type 
ActKR 
The polyketide chain is represented in yellow and actKR in transparent white surface. 
(A) Ligand docking results suggest that after the PPT phosphate binds within the arginine patch 
groove (blue surface), the polyketide chain enters the substrate pocket underneath the gate 
residues P94 and M194 (green spheres) in order to access the active site. 
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(B) The polyketide intermediate is steered toward the active site by the bulky residues V151, 
F189, and V198 (purple sticks), which presumably constrain chain movement. 
(C) Ligand docking also suggests that T145 (teal) may stabilize the C11-oxyanion after C12 
deprotonation through hydrogen-bonding, thus lowering the C12-proton pKa and allowing C7-
C12 cyclization to occur. S158 (teal) may stabilize the resulting C7-oxyanion through water-
mediated hydrogen-bonding. Both T145 and S158 are highly conserved among type II KRs. 
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Table 1. Kinetic Parameters for the Reduction of trans-1-Decalone and interaction with NADPH and 
ACP by Wild-Type and Mutants of Actinorhodin Ketoreductase 
 kcat (s-1) Km (mM) 
kcat/Km 
(s-1 mM-1) 
KD (µM) 
NADPH  
KD (µM) 
ACP 
WT 2.55 ± 0.12 0.76 ± 0.09 3.23 ± 0.32 - - 
D109E 1.17 ± 0.12 0.71 ± 0.18 1.64 ± 0.45 - - 
D109R 0.078 ± 0.01 1.25 ± 0.40 0.062 ± 0.021 - - 
S144C Inactive - - 
T145A 0.18 ± 0.008 0.42 ± 0.06 0.42 ± 0.06 - - 
G146V Inactive - - 
V151A Inactive - - 
V151L 1.24 ± 0.07 0.97 ± 0.12 1.28 ± 0.18 - - 
A154G 1.33 ± 0.16 0.50 ± 0.18 2.68 ± 1.03 - - 
F189A 0.049 ± 0.005 8.63 ± 2.01 0.0057 ± 0.0015 - - 
F189W Substrate Inhibition - - 
M194W 0.43 ± 0.06 3.22 ± 0.65 0.13 ± 0.03 - - 
V198A 0.24 ± 0.01 15.50 ± 1.49 0.016 ± 0.002 - - 
V198Ga 
1.3 ± 0.1 0.32 ± 0.06 5.36 ± 1.12 0.060 ± 0.017 
- - 
Y202Aa 
2.0 ± 0.3 1.80 ± 0.09 1.07 ± 0.09 1.69 ± 0.16 
- - 
Y202F 2.01 ± 0.17 0.40 ± 0.11 5.01 ± 1.44 - - 
      
WTb 2.00 ± 0.06 1.19 ± 0.02 1.68 ± 0.08 1.52 ± 0.09 0.20 ± 0.08 
R38A 0.16 ± 0.03 1.45 ± 0.02 0.11 ± 0.02 4.30 ± 0.40 1.52 ± 0.12 
R65A 1.97 ± 0.07 1.24 ± 0.02 1.59 ± 0.07 1.83 ± 0.21 0.53 ± 0.11 
R93A 1.13 ± 0.05 1.21 ± 0.01 0.94 ± 0.05 6.43 ± 0.68 0.53 ± 0.07 
R177A 1.99 ± 0.03 1.26 ± 0.01 1.58 ± 0.03 1.17 ± 0.10 0.49 ± 0.12 
R220A 1.78 ± 0.06 1.18 ± 0.02 1.51 ± 0.06 1.99 ± 0.16 0.61 ± 0.10 
a. Kinetic parameters determined using Hill equation: v = (Vmax × [S]n)/(K’ + [S]n). The Hill 
coefficient (n) is listed under the mutation identifier. 
b. Kinetic parameters determined independently. The relative rate parameters for the arginine 
mutations below should be compared to this value for WT. 
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Table 2. Oxidation of S-(+)-Tetralol and R-(-)-Tetralol by Wild-Type and Mutants of 
Actinorhodin Ketoreductase 
 
General 
Mutation 
Location 
S-(+)-Tetralol 
kcat/Kma 
R-(-)-Tetralol 
kcat/Kma S:R Activity Ratiob 
s-1mM-1 % s-1mM-1 % 
WT  0.035 100 0.010 100 3.5 
D109E Surface 0.0063 18 0.0012 12 5.3 
D109R Surface Inactive 
S144C Pocket Inactive 
T145A Pocket .0041 12 Inactive NA 
G146V Pocket Inactive 
V151A Pocket Inactive 
V151L Pocket Substrate Inhibition 0.026 260 NA 
A154G Pocket 0.018 51 0.0021 21 8.6 
F189A Pocket 0.0070 20 Inactive NA 
F189W Pocket 0.029 83 0.0026 26 11.2 
M194W Pocket 0.034 97 Inactive NA 
V198A Pocket 0.023 66 0.020 200 1.2 
V198G Pocket 0.0012 3 0.00083 8 1.5 
Y202A α6-α7 Loop 0.039 111 0.0078  22 5.0 
Y202F α6-α7 Loop 0.016 46 0.0048 14 3.3 
a. Catalytic specificity (kcat/Km) expressed as percentage of wild-type value. 
b. Ratio of S-tetralol to R-tetralol kcat/Km values. 
c. Summary of analyses 
See also Table S1 and Figure S1. 
 
 
